Sign In
Buy HEPA
$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q2 2020 Results - Earnings Call Transcript
09:32am, Friday, 07'th Aug 2020
Novo Nordisk A/S (NYSE:NVO) Q2 2020 Earnings Conference Call August 6, 2020 07:00 ET Company Participants Lars Fruergaard Jorgensen - Chief Executive Officer Mads Krogsgaard Thomsen - EVP & Chief
Amarin Earnings, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:AMRN)
09:11pm, Thursday, 06'th Aug 2020
Amarin reports better than expected financial numbers for second quarter. CytoDyn reports positive DSMC opinion for COVID-19 trial.
Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes
12:00am, Thursday, 06'th Aug 2020
Fractyl's first close of $55 million will be used to support the Revita T2Di pivotal US clinical trial of Revita DMR to treat type 2 diabetes.
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial
11:15am, Wednesday, 05'th Aug 2020
(NASDAQ:HEPA), a biopharmaceutical company focusing on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that
Merck & Co to repurpose failed obesity drug for NASH -
07:21am, Wednesday, 05'th Aug 2020
Merck & Co is to pay $10 million to Hanmi to repurpose a drug discarded by Johnson & Johnson in obesity into a therapy for the fatty liver disease also known as NASH.
GENFIT : la technologie NIS4 objet d'une publication dans The Lancet Gastroenterology
07:20am, Wednesday, 05'th Aug 2020
(AOF) - Genfit annonce que les données décrivant la dérivation et la validation de NIS4 ont été acceptées pour publication dans The Lancet Gastroenterology & Hepatology. NIS4 est la technologie
GENFIT : la technologie NIS4 objet d’une publication dans The Lancet Gastroenterology
07:15am, Wednesday, 05'th Aug 2020
(AOF) - Genfit annonce que les données décrivant la dérivation et la validation de NIS4 ont été acceptées pour publication dans The Lancet Gastroenterology & Hepatology. NIS4 est la technolo
GENFIT : la technologie NIS4 objet d’une publication dans The Lancet Gastroenterology | Zone bourse
07:05am, Wednesday, 05'th Aug 2020Enanta Pharmaceuticals Inc (ENTA) Q3 2020 Earnings Call Transcript | The Motley Fool
05:31am, Wednesday, 05'th Aug 2020
ENTA earnings call for the period ending June 30, 2020.
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
Merck, Hanmi sign $870M deal for NASH drug
05:43pm, Tuesday, 04'th Aug 2020
Hanmi will retain options for the drug, efinopegdutide, in Korea under the deal, in which Merck is paying the Seoul-based company $10 million upfront and up to $860 for development, regulatory and com
Durect Corp (DRRX) Q2 2020 Earnings Call Transcript | The Motley Fool
05:00am, Tuesday, 04'th Aug 2020
DRRX earnings call for the period ending June 30, 2020.
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for NASH
INVEST Pitch Perfect winner spotlight: Pleiogenix eyes road ahead for liver disease drug
04:21pm, Monday, 03'rd Aug 2020
The company is hoping to close its seed funding round in the next six months and aims to be in a position to seek regulatory approval for its lead asset, PLX888, in acute alcoholic hepatitis in 2023.
